Skip to main content
Top
Gepubliceerd in:

22-01-2022

The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States

Auteurs: Marwan Alrasheed, Jeff Jianfei Guo, Alex C. Lin, Patricia R. Wigle, Angelica Hardee, Ana L. Hincapie

Gepubliceerd in: Quality of Life Research | Uitgave 8/2022

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is a significant epidemiological problem with rising prevalence. Due to limited literature, the objective of this study is to examine the association between polypharmacy and health-related quality of life (QoL) in NAFLD adult patients.

Methods

A retrospective observational study design was conducted to analyze health data collected by Steatohepatitis Clinical Research Network (NASH CRN). Patients were classified as receiving a polypharmacy therapy with five or more medications in their first screening visit. QoL was measured using the Short Form 36 (SF-36) instrument. Each patient self-reported the SF-36 form during the screening visit was compared between polypharmacy and non-polypharmacy groups using Wilcoxon Rank Sum test. Multivariable generalized linear models and multinomial logistic regression were performed to examine each predictor and its effect on QoL.

Results

Data included 1067 NAFLD adult patients; 834 patients used polypharmacy. The mean age was 48.64 years, and most patients were female (62%). Comparing NAFLD patients without steatohepatitis, borderline NASH, and definite NASH, the non-polypharmacy group had a significantly higher QoL than the polypharmacy group in Physical Component Summary (PCS) (86.25 vs 66.88, 85 vs 67.5, and 79.375 vs 63.12, respectively, all p < 0.01) and Mental Component Summary (MCS) (83.5 vs 73.38, 78.75 vs 67.62, and 78.75 vs 70.65, respectively, all p < 0.01).

Discussion and conclusion

Adults with NAFLD and polypharmacy have lower QoL than adults with NAFLD and non-polypharmacy. Number of medications had a significant negative impact on PCS, MCS, and all SF-36 domains except mental health, role physical limitation and role emotional limitation domains. Other factors that affect QoL negatively in NAFLD adult patients are female gender, obesity, diabetes, depression, and unemployment. Higher income had favorable effect on QoL.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Ludwig, J., Viggiano, T. R., McGill, D. B., & Oh, B. J. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings, 55(7), 434–438.PubMed Ludwig, J., Viggiano, T. R., McGill, D. B., & Oh, B. J. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings, 55(7), 434–438.PubMed
3.
go back to reference Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., et al. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328–357.PubMedCrossRef Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., et al. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328–357.PubMedCrossRef
4.
go back to reference Cholankeril, G., Wong, R. J., Hu, M., Perumpail, R. B., Yoo, E. R., Puri, P., et al. (2017). Liver Transplantation for nonalcoholic steatohepatitis in the US: Temporal trends and outcomes. Digestive Diseases and Sciences, 62(10), 2915–2922.PubMedCrossRef Cholankeril, G., Wong, R. J., Hu, M., Perumpail, R. B., Yoo, E. R., Puri, P., et al. (2017). Liver Transplantation for nonalcoholic steatohepatitis in the US: Temporal trends and outcomes. Digestive Diseases and Sciences, 62(10), 2915–2922.PubMedCrossRef
5.
go back to reference Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., et al. (2015). Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology, 148(3), 547–555.PubMedCrossRef Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., et al. (2015). Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology, 148(3), 547–555.PubMedCrossRef
6.
go back to reference Younossi, Z. M., Stepanova, M., Younossi, Y., Golabi, P., Mishra, A., Rafiq, N., et al. (2020). Epidemiology of chronic liver diseases in the USA in the past three decades. Gut, 69(3), 564–568.PubMedCrossRef Younossi, Z. M., Stepanova, M., Younossi, Y., Golabi, P., Mishra, A., Rafiq, N., et al. (2020). Epidemiology of chronic liver diseases in the USA in the past three decades. Gut, 69(3), 564–568.PubMedCrossRef
7.
go back to reference Vernon, G., Baranova, A., & Younossi, Z. M. (2011). Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics, 34(3), 274–285.CrossRef Vernon, G., Baranova, A., & Younossi, Z. M. (2011). Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics, 34(3), 274–285.CrossRef
8.
go back to reference Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., et al. (2011). Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology, 140(1), 124–131.PubMedCrossRef Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., et al. (2011). Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology, 140(1), 124–131.PubMedCrossRef
10.
go back to reference Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., et al. (2005). The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology, 129(1), 113–121.PubMedCrossRef Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., et al. (2005). The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology, 129(1), 113–121.PubMedCrossRef
11.
go back to reference Younossi, Z., & Henry, L. (2016). Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology, 150(8), 1778–1785.PubMedCrossRef Younossi, Z., & Henry, L. (2016). Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology, 150(8), 1778–1785.PubMedCrossRef
12.
go back to reference Mohamad, B., Shah, V., Onyshchenko, M., Elshamy, M., Aucejo, F., Lopez, R., et al. (2016). Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatology International, 10(4), 632–639.PubMedCrossRef Mohamad, B., Shah, V., Onyshchenko, M., Elshamy, M., Aucejo, F., Lopez, R., et al. (2016). Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatology International, 10(4), 632–639.PubMedCrossRef
13.
go back to reference Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 17(1), 230.PubMedPubMedCentralCrossRef Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 17(1), 230.PubMedPubMedCentralCrossRef
14.
go back to reference Bakaki, P. M., Horace, A., Dawson, N., Winterstein, A., Waldron, J., Staley, J., et al. (2018). Defining pediatric polypharmacy: A scoping review. PLoS ONE, 13(11), e0208047.PubMedPubMedCentralCrossRef Bakaki, P. M., Horace, A., Dawson, N., Winterstein, A., Waldron, J., Staley, J., et al. (2018). Defining pediatric polypharmacy: A scoping review. PLoS ONE, 13(11), e0208047.PubMedPubMedCentralCrossRef
16.
go back to reference Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015). Trends in prescription drug use among adults in the United States From 1999–2012. JAMA, 314(17), 1818.PubMedPubMedCentralCrossRef Kantor, E. D., Rehm, C. D., Haas, J. S., Chan, A. T., & Giovannucci, E. L. (2015). Trends in prescription drug use among adults in the United States From 1999–2012. JAMA, 314(17), 1818.PubMedPubMedCentralCrossRef
19.
go back to reference Ware, J. E., & Gandek, B. (1998). Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. Journal of Clinical Epidemiology, 51(11), 903–912.PubMedCrossRef Ware, J. E., & Gandek, B. (1998). Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. Journal of Clinical Epidemiology, 51(11), 903–912.PubMedCrossRef
20.
go back to reference Dan, A. A., Kallman, J. B., Wheeler, A., Younoszai, Z., Collantes, R., Bondini, S., et al. (2007). Health-related quality of life in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 26(6), 815–820.CrossRef Dan, A. A., Kallman, J. B., Wheeler, A., Younoszai, Z., Collantes, R., Bondini, S., et al. (2007). Health-related quality of life in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics, 26(6), 815–820.CrossRef
21.
go back to reference Assimakopoulos, K., Karaivazoglou, K., Tsermpini, E.-E., Diamantopoulou, G., & Triantos, C. (2018). Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. Journal of Psychosomatic Research, 112, 73–80.PubMedCrossRef Assimakopoulos, K., Karaivazoglou, K., Tsermpini, E.-E., Diamantopoulou, G., & Triantos, C. (2018). Quality of life in patients with nonalcoholic fatty liver disease: A systematic review. Journal of Psychosomatic Research, 112, 73–80.PubMedCrossRef
22.
go back to reference Sayiner, M., Stepanova, M., Pham, H., Noor, B., Walters, M., & Younossi, Z. M. (2016). Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenteroligy, 3(1), e000106.CrossRef Sayiner, M., Stepanova, M., Pham, H., Noor, B., Walters, M., & Younossi, Z. M. (2016). Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenteroligy, 3(1), e000106.CrossRef
23.
go back to reference Chawla, K. S., Talwalkar, J. A., Keach, J. C., Malinchoc, M., Lindor, K. D., & Jorgensen, R. (2016). Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH). BMJ Open Gastroenterology, 3(1), e000069.PubMedPubMedCentralCrossRef Chawla, K. S., Talwalkar, J. A., Keach, J. C., Malinchoc, M., Lindor, K. D., & Jorgensen, R. (2016). Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH). BMJ Open Gastroenterology, 3(1), e000069.PubMedPubMedCentralCrossRef
24.
go back to reference Patel, P. J., Hayward, K. L., Rudra, R., Horsfall, L. U., Hossain, F., Williams, S., et al. (2017). Multimorbidity and polypharmacy in diabetic patients with NAFLD. Medicine (Baltimore), 96, e6761.CrossRef Patel, P. J., Hayward, K. L., Rudra, R., Horsfall, L. U., Hossain, F., Williams, S., et al. (2017). Multimorbidity and polypharmacy in diabetic patients with NAFLD. Medicine (Baltimore), 96, e6761.CrossRef
25.
go back to reference Spengler, E. K., & Loomba, R. (2015). Recommendations for diagnosis, referral for liver biopsy, and treatment of NAFLD and NASH. Mayo Clinic Proceedings, 90(9), 1233–1246.PubMedCrossRef Spengler, E. K., & Loomba, R. (2015). Recommendations for diagnosis, referral for liver biopsy, and treatment of NAFLD and NASH. Mayo Clinic Proceedings, 90(9), 1233–1246.PubMedCrossRef
26.
go back to reference Babcock, Z. R., Kogut, S. J., & Vyas, A. (2020). Association between polypharmacy and health-related quality of life among cancer survivors in the United States. Journal of Cancer Survivorship, 14(1), 89–99.PubMedCrossRef Babcock, Z. R., Kogut, S. J., & Vyas, A. (2020). Association between polypharmacy and health-related quality of life among cancer survivors in the United States. Journal of Cancer Survivorship, 14(1), 89–99.PubMedCrossRef
27.
go back to reference Schenker, Y., Park, S. Y., Jeong, K., Pruskowski, J., Kavalieratos, D., Resick, J., et al. (2019). Associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness. Journal of General Internal Medicine, 34(4), 559–566.PubMedPubMedCentralCrossRef Schenker, Y., Park, S. Y., Jeong, K., Pruskowski, J., Kavalieratos, D., Resick, J., et al. (2019). Associations between polypharmacy, symptom burden, and quality of life in patients with advanced, life-limiting illness. Journal of General Internal Medicine, 34(4), 559–566.PubMedPubMedCentralCrossRef
28.
go back to reference Okoli, C., de los Rios, P., Eremin, A., Brough, G., Young, B., & Short, D. (2020). Relationship between polypharmacy and quality of life among people in 24 Countries living with HIV. Preventing Chronic Disease, 17, 190359.CrossRef Okoli, C., de los Rios, P., Eremin, A., Brough, G., Young, B., & Short, D. (2020). Relationship between polypharmacy and quality of life among people in 24 Countries living with HIV. Preventing Chronic Disease, 17, 190359.CrossRef
29.
go back to reference (2003). Nonalcoholic steatohepatitis clinical research network. Hepatology 37(2):244 (2003). Nonalcoholic steatohepatitis clinical research network. Hepatology 37(2):244
32.
go back to reference Woźniak, I., Kolonko, A., Chudek, J., Nowak, Ł, Farnik, M., & Więcek, A. (2018). Influence of polypharmacy on the quality of life in stable kidney transplant recipients. Transplantation Proceedings, 50(6), 1896–1899.PubMedCrossRef Woźniak, I., Kolonko, A., Chudek, J., Nowak, Ł, Farnik, M., & Więcek, A. (2018). Influence of polypharmacy on the quality of life in stable kidney transplant recipients. Transplantation Proceedings, 50(6), 1896–1899.PubMedCrossRef
33.
go back to reference Alexander, H. B., Broshek, D. K., & Quigg, M. (2018). Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status. Epilepsy & Behavior, 78, 96–99.CrossRef Alexander, H. B., Broshek, D. K., & Quigg, M. (2018). Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status. Epilepsy & Behavior, 78, 96–99.CrossRef
34.
go back to reference Vyas, A., Kang, F., & Barbour, M. (2020). Association between polypharmacy and health-related quality of life among US adults with cardiometabolic risk factors. Quality of Life Research, 29(4), 977–986.PubMedCrossRef Vyas, A., Kang, F., & Barbour, M. (2020). Association between polypharmacy and health-related quality of life among US adults with cardiometabolic risk factors. Quality of Life Research, 29(4), 977–986.PubMedCrossRef
35.
go back to reference Golabi, P., Otgonsuren, M., Cable, R., Felix, S., Koenig, A., Sayiner, M., et al. (2016). Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health and Quality of Life Outcomes, 14, 18.PubMedPubMedCentralCrossRef Golabi, P., Otgonsuren, M., Cable, R., Felix, S., Koenig, A., Sayiner, M., et al. (2016). Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health and Quality of Life Outcomes, 14, 18.PubMedPubMedCentralCrossRef
36.
go back to reference Kennedy-Martin, T., Bae, J. P., Paczkowski, R., & Freeman, E. (2017). Health-related quality of life burden of nonalcoholic steatohepatitis: A robust pragmatic literature review. Journal of Patient-Reported Outcomes, 2, 28.PubMedCrossRef Kennedy-Martin, T., Bae, J. P., Paczkowski, R., & Freeman, E. (2017). Health-related quality of life burden of nonalcoholic steatohepatitis: A robust pragmatic literature review. Journal of Patient-Reported Outcomes, 2, 28.PubMedCrossRef
37.
go back to reference Bezemer, G., Van Gool, A. R., Verheij-Hart, E., Hansen, B. E., Lurie, Y., Esteban, J. I., et al. (2012). Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterology, 12(1), 11.PubMedPubMedCentralCrossRef Bezemer, G., Van Gool, A. R., Verheij-Hart, E., Hansen, B. E., Lurie, Y., Esteban, J. I., et al. (2012). Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterology, 12(1), 11.PubMedPubMedCentralCrossRef
38.
go back to reference Huber, Y., Boyle, M., Hallsworth, K., Tiniakos, D., Straub, B. K., Labenz, C., et al. (2019). Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clinical Gastroenterology and Hepatology, 17(10), 2085-2092.e1.PubMedCrossRef Huber, Y., Boyle, M., Hallsworth, K., Tiniakos, D., Straub, B. K., Labenz, C., et al. (2019). Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation. Clinical Gastroenterology and Hepatology, 17(10), 2085-2092.e1.PubMedCrossRef
39.
go back to reference David, K., Kowdley, K. V., Unalp, A., Kanwal, F., Brunt, E. M., & Schwimmer, J. B. (2009). Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology, 49(6), 1904–1912.PubMedCrossRef David, K., Kowdley, K. V., Unalp, A., Kanwal, F., Brunt, E. M., & Schwimmer, J. B. (2009). Quality of life in adults with nonalcoholic fatty liver disease: Baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology, 49(6), 1904–1912.PubMedCrossRef
40.
go back to reference Alrasheed, M., Alsuhibani, A., Hincapie, A. L., Welge, J. (2021) Comparison of quality of life between men and women with chronic liver diseases using chronic liver disease questionnaire (CLDQ): A meta-analysis. In Pharmacoepidemiology and Drug Safety 2021 Aug 1 (Vol. 30, pp. 181–181). 111 RIVER ST, HOBOKEN 07030–5774, NJ USA: WILEY. Alrasheed, M., Alsuhibani, A., Hincapie, A. L., Welge, J. (2021) Comparison of quality of life between men and women with chronic liver diseases using chronic liver disease questionnaire (CLDQ): A meta-analysis. In Pharmacoepidemiology and Drug Safety 2021 Aug 1 (Vol. 30, pp. 181–181). 111 RIVER ST, HOBOKEN 07030–5774, NJ USA: WILEY.
41.
go back to reference Younossi, Z. M., Stepanova, M., Sulkowski, M., Naggie, S., Henry, L., & Hunt, S. (2016). Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. Journal of Viral Hepatitis, 23(11), 857–865.PubMedCrossRef Younossi, Z. M., Stepanova, M., Sulkowski, M., Naggie, S., Henry, L., & Hunt, S. (2016). Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. Journal of Viral Hepatitis, 23(11), 857–865.PubMedCrossRef
42.
go back to reference Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., et al. (2017). Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology (Baltimore, MD), 65(5), 1557–1565.CrossRef Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., et al. (2017). Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology (Baltimore, MD), 65(5), 1557–1565.CrossRef
43.
go back to reference Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., et al. (2017). Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology, 67(6), 1265–1273.PubMedCrossRef Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., et al. (2017). Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology, 67(6), 1265–1273.PubMedCrossRef
44.
go back to reference Choi, J. M., Chung, G. E., Kang, S. J., Kwak, M.-S., Yang, J. I., Park, B., et al. (2021). Association between anxiety and depression and nonalcoholic fatty liver disease. Frontiers in Medicine, 7, 1068.CrossRef Choi, J. M., Chung, G. E., Kang, S. J., Kwak, M.-S., Yang, J. I., Park, B., et al. (2021). Association between anxiety and depression and nonalcoholic fatty liver disease. Frontiers in Medicine, 7, 1068.CrossRef
45.
go back to reference Elliott, T. E., Renier, C. M., & Palcher, J. A. (2003). Chronic pain, depression, and quality of life: Correlations and predictive value of the SF-36. Chronic Pain, 4, 331. Elliott, T. E., Renier, C. M., & Palcher, J. A. (2003). Chronic pain, depression, and quality of life: Correlations and predictive value of the SF-36. Chronic Pain, 4, 331.
46.
go back to reference McKee-Ryan, F., Song, Z., Wanberg, C. R., & Kinicki, A. J. (2005). Psychological and physical well-being during unemployment: A meta-analytic study. Journal of Applied Psychology, 90(1), 53.PubMedCrossRef McKee-Ryan, F., Song, Z., Wanberg, C. R., & Kinicki, A. J. (2005). Psychological and physical well-being during unemployment: A meta-analytic study. Journal of Applied Psychology, 90(1), 53.PubMedCrossRef
47.
go back to reference Paul, K. I., & Moser, K. (2009). Unemployment impairs mental health: Meta-analyses. Journal of Vocational Behavior, 74(3), 264–282.CrossRef Paul, K. I., & Moser, K. (2009). Unemployment impairs mental health: Meta-analyses. Journal of Vocational Behavior, 74(3), 264–282.CrossRef
48.
49.
go back to reference Rodriguez, E. (2001). Keeping the unemployed healthy: The effect of means-tested and entitlement benefits in Britain, Germany, and the United States. American Journal of Public Health, 91(9), 1403–1411.PubMedPubMedCentralCrossRef Rodriguez, E. (2001). Keeping the unemployed healthy: The effect of means-tested and entitlement benefits in Britain, Germany, and the United States. American Journal of Public Health, 91(9), 1403–1411.PubMedPubMedCentralCrossRef
51.
go back to reference Bunevicius, A. (2017). Reliability and validity of the SF-36 Health Survey Questionnaire in patients with brain tumors: A cross-sectional study. Health and Quality of Life Outcomes, 15, 92.PubMedPubMedCentralCrossRef Bunevicius, A. (2017). Reliability and validity of the SF-36 Health Survey Questionnaire in patients with brain tumors: A cross-sectional study. Health and Quality of Life Outcomes, 15, 92.PubMedPubMedCentralCrossRef
52.
go back to reference Brazier, J. E., Harper, R., Jones, N. M., O’Cathain, A., Thomas, K. J., Usherwood, T., et al. (1992). Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ, 305(6846), 160–164.PubMedPubMedCentralCrossRef Brazier, J. E., Harper, R., Jones, N. M., O’Cathain, A., Thomas, K. J., Usherwood, T., et al. (1992). Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ, 305(6846), 160–164.PubMedPubMedCentralCrossRef
53.
go back to reference Failde, I., & Ramos, I. (2000). Validity and reliability of the SF-36 Health Survey Questionnaire in patients with coronary artery disease. Journal of Clinical Epidemiology, 53(4), 359–365.PubMedCrossRef Failde, I., & Ramos, I. (2000). Validity and reliability of the SF-36 Health Survey Questionnaire in patients with coronary artery disease. Journal of Clinical Epidemiology, 53(4), 359–365.PubMedCrossRef
54.
go back to reference McHorney, C. A., Ware, J. E., Lu, J. F. R., & Sherbourne, C. D. (1994). The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32(1), 40–66.PubMedCrossRef McHorney, C. A., Ware, J. E., Lu, J. F. R., & Sherbourne, C. D. (1994). The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32(1), 40–66.PubMedCrossRef
55.
go back to reference Posthouwer, D., Plug, I., van der Bom, J. G., Fischer, K., Rosendaal, F. R., & Mauser-Bunschoten, E. P. (2005). Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica, 90(6), 846–850.PubMed Posthouwer, D., Plug, I., van der Bom, J. G., Fischer, K., Rosendaal, F. R., & Mauser-Bunschoten, E. P. (2005). Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica, 90(6), 846–850.PubMed
Metagegevens
Titel
The effect of polypharmacy on quality of life in adult patients with nonalcoholic fatty liver disease in the United States
Auteurs
Marwan Alrasheed
Jeff Jianfei Guo
Alex C. Lin
Patricia R. Wigle
Angelica Hardee
Ana L. Hincapie
Publicatiedatum
22-01-2022
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 8/2022
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-022-03090-6

Andere artikelen Uitgave 8/2022

Quality of Life Research 8/2022 Naar de uitgave